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Abstract
Background
Forty million adults in the US suffer from anxiety disorders, making these the most common
forms of mental illness. Transient receptor potential channel canonical subfamily (TRPC)
members 4 and 5 are non-selective cation channels highly expressed in regions of the cor-
tex and amygdala, areas thought to be important in regulating anxiety. Previous work with
null mice suggests that inhibition of TRPC4 and TRPC5 may have anxiolytic effects.
HC-070 in vitro
To assess the potential of TRPC4/5 inhibitors as an avenue for treatment, we invented a
highly potent, small molecule antagonist of TRPC4 and TRPC5 which we call HC-070. HC-
070 inhibits recombinant TRPC4 and TRPC5 homomultimers in heterologous expression
systems with nanomolar potency. It also inhibits TRPC1/5 and TRPC1/4 heteromultimers
with similar potency and reduces responses evoked by cholecystokinin tetrapeptide (CCK-
4) in the amygdala. The compound is >400-fold selective over a wide range of molecular tar-
gets including ion channels, receptors, and kinases.
HC-070 in vivo
Upon oral dosing in mice, HC-070 achieves exposure levels in the brain and plasma
deemed sufficient to test behavioral activity. Treatment with HC-070 attenuates the anxio-
genic effect of CCK-4 in the elevated plus maze (EPM). The compound recapitulates the
phenotype observed in both null TRPC4 and TRPC5 mice in a standard EPM. Anxiolytic
and anti-depressant effects of HC-070 are also observed in pharmacological in vivo tests
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including marble burying, tail suspension and forced swim. Furthermore, HC-070 amelio-
rates the increased fear memory induced by chronic social stress. A careful evaluation of
the pharmacokinetic-pharmacodynamic relationship reveals that substantial efficacy is
observed at unbound brain levels similar to, or even lower than, the 50% inhibitory concen-
tration (IC50) recorded in vitro, increasing confidence that the observed effects are indeed
mediated by TRPC4 and/or TRPC5 inhibition. Together, this experimental data set intro-
duces a novel, high quality, small molecule antagonist of TRPC4 and TRPC5 containing
channels and supports the targeting of TRPC4 and TRPC5 channels as a new mechanism
of action for the treatment of psychiatric symptoms.
Introduction
According to the World Health Organization, approximately 800,000 people commit suicide
each year and many more attempt it. Among people aged 15–29, suicide is the second leading
cause of death [1]. Many of these individuals suffer from anxiety and/or depression. While
improved access to counseling, prevention programs, and existing medications would likely
reduce these deaths, novel treatment options are also of importance. In the STARD trial of
more than 4,000 patients with nonpsychotic depression approximately 30% of the patients
failed to reach remission even after treatment with four different medications [2] and contin-
ued to experience residual symptoms [3] that significantly impacted their quality of life.
TRPC4 and TRPC5 are non-selective cation channels that are widely expressed throughout
the brain, with particularly high transcript levels in the cortex and amygdala [4]. They can
exist as homomultimers or as heteromultimers with TRPC1 [5]. Stimulation of G-alpha q type
G-protein coupled receptors (GPCRs) induces TRPC4 and TRPC5 currents in heterologous
expression systems [6] and is thought to be a physiologically relevant activator of the channels
[7, 8]. Activation of G-alpha q coupled-GPCRs has also been implicated in fear-related behav-
iors, and acute engagement of the signaling pathway via a synthetic receptor is sufficient to
induce behaviors indicative of anxiety [9]. G-alpha i/o coupled GPCRs also have the ability to
activate TRPC4, perhaps even more robustly than G-alpha q receptors, positioning these chan-
nels as transducers of an even broader array of signals [10, 11].
Genetic deletion of either TRPC4 [8] or TRPC5 [7] reduces anxiety behaviors in mice. Null
animals show increased exploratory behaviors in both open field tests and in the elevated plus
maze (EPM) [7, 8]. These findings were recapitulated with early pharmacological antagonists
[12]. Some of the observed effects may be due to a reduction in cholecystokinin receptor B
(CCKB) and metabotropic glutamate receptor (mGluR) signaling in the amygdala, as brain
slices from null mice show attenuated responses to activation of those receptors [7, 8]. These
data suggest that TRPC4 and TRPC5 are downstream effectors of these two GPCR pathways.
While some small molecule inhibitors of TRPC4 and TRPC5 have been described, these
probes have suffered from a lack of potency, inhibiting channels only at micromolar (μM) lev-
els [12, 13]. This relative lack of potency makes assessing the specificity of these compounds
difficult. In addition, little has been reported about the pharmacokinetic (PK) properties of
these molecules.
Based on the potential biological importance of TRPC4 and TRPC5 and the lack of high
potency inhibitors, we sought to develop a high-quality compound suitable to elucidate the in
vivo function of these channels in the CNS. To this end, we performed a fluorescence-based
high throughput screen, confirmed compounds of interest with electrophysiology, and
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optimized the potency and PK properties of the compounds through iterative cycles of com-
pound synthesis, testing, and design. One of the resulting compounds was HC-070. HC-070
potently and selectively inhibits TRPC4 and TRPC5. The in vitro properties of this compound
are very similar to a compound we previously invented and disclosed, HC-608 [14, 15], which
has also been referred to as Pico145 [16]. In addition to blocking heterologously expressed
channels, we show that HC-070 attenuates neuronal activity recorded from the amygdala.
Oral dosing of HC-070 results in brain and plasma exposures sufficient to test behavioral
activity. We characterized the behavioral effects of HC-070 treatment in the EPM test with and
without CCK-4 challenge, the marble-burying test, and a model of chronic social stress that
induced hyper-fear learning and memory. In each of these animal models, treatment with HC-
070 reduces anxiety/fear behaviors without impacting locomotor activity. HC-070 also has
antidepressant-like effects in the tail suspension and forced swim tests, where it significantly
reduces immobility. Detailed modeling of the pharmacokinetic-pharmacodynamic (PK-PD)
relationship indicates that efficacy in the forced swim test coincides with unbound brain levels
near the IC50 for TRPC4 and TRPC5 inhibition and further substantiates the finding that the
observed behavioral effects are on target.
Taken together, these data suggest that TRPC4 and TRPC5 channels may be important tar-
gets for the treatment of anxiety and depression. HC-070 is a potent and selective compound
which should be useful in further unraveling the function of these channels.
Results
In vitro profiling
In order to identify small molecule inhibitors of TRPC5, we performed a high-throughput
screen of ~65,000 compounds. The average Z’, a metric of assay robustness, was 0.65 ± 0.07,
indicating very good separation between the positive and negative controls. This effort resulted
in the identification of several classes of compounds that were subsequently confirmed as
being TRPC5 inhibitors in electrophysiology. We chose the class of compounds that we
thought exhibited the best combination of potency and drug-like properties and performed
iterative cycles of compound design, synthesis, and testing to identify a high-quality inhibitor.
This effort resulted in the invention of HC-070 (Fig 1 panel A) [14, 15]. This compound is
highly similar to HC-608 (Fig 1 panel B), which we also invented during this effort [12, 14, 15],
and was recently published as Pico145 [16]. Both compounds are readily synthesizable in three
steps from commercially available starting materials [14].
HC-070 inhibited calcium influx into recombinantly-expressed human TRPC5 (hTRPC5)
(Fig 1 panel C) expressing cells with an IC50 of 9.3 ± 0.9 nM in a concentration-response study
performed in octuplicate, covering concentrations ranging from 1 pM to 1 μM. More than
90% inhibition was observed at concentrations of 31 nM or above, with complete block at the
highest concentrations. HC-070 also attenuated TRPC4-activity, inhibiting calcium influx
with an IC50 of 46.0 ± 3.9 nM (Fig 1 panel D). Again, complete inhibition was observed. Com-
parable results were achieved with HC-608 (Fig 1 panels C and D). Example time course data
from cells expressing TRPC5 are shown in S1 Fig panels A and B. Example time course data
from cells expressing TRPC4 are shown in S1 Fig panels C and D.
In whole-cell manual patch clamp, HC-070 inhibited lanthanum-activated hTRPC5-me-
diated currents with an IC50 of 0.52 nM (Table 1). This is significantly more potent than the
IC50 we observed in the fluorometric assay. Increased potency in electrophysiological com-
pared to fluorometric assays has often been observed and reported for other TRP channels
[17].
HC-070, a TRPC4/5 inhibitor, ameliorates behaviors associated with anxiety and depression in mice
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Fig 1. Structures and activity in fluorometric assays of HC-070 and HC-608. The chemical structures of (A) HC-070 and
(B) HC-608 (Pico145). (C) Inhibition of hTRPC5 by HC-070 and HC-608 in indicator-assisted calcium influx analysis.
Concentrations tested ranged from 1 picomolar (pM) to 1 μM. Each data point represents the average of 8 measurements
from a 384-well plate. Error bars show the standard deviation. The IC50 values were 9.3 ± 0.9 and 6.2 ± 0.5 nanomolar (nM),
respectively. (D) Inhibition of hTRPC4 by HC-070 and HC-608 over the same range of concentrations. The IC50 values were
46.0 ± 3.9 nM and 32.5 ± 1.8 nM, respectively (n = 8). Error bars represent the standard deviation.
https://doi.org/10.1371/journal.pone.0191225.g001
Table 1. HC-070 inhibits recombinantly expressed TRPC4 and TRPC5, as well as TRPC1-containing heteromultimers, in whole-cell manual patch clamp.
HC-070
CHANNEL CURRENT ACTIVATION Cells Tested IC50 (nM)
mTRPC5 La3+ (80 μM) 5 0.55 ± 0.11
hTRPC5 La3+ (80 μM) 5 0.52 ± 0.11
rTRPC5 La3+ (80 μM) 5 0.32 ± 0.05
mTRPC5 20 μM carbachol/M1R 13 ~3.4 ±0.6
hTRPC5 20 μM carbachol/M1R 5 2.0 ± 1.5
mTRPC4 10 μM carbachol/M2R 7 ~1.8 ±0.2
hTRPC4 10 μM carbachol/M2R 5 0.49 ± 0.10
hTRPC1/hTRPC5 La3+ (80 μM) 5 1.4 ± 0.6
hTRPC1/hTRPC5 20 μM carbachol/M1R 5 4.4 ± 1.0
hTRPC1/hTRPC4 10 μM carbachol/M2R 5 1.3 ± 0.4
Listed IC50 values are mean ± S.D.
—The IC50 was calculated from percent inhibition values combined from multiple, different cells, and then fitted with the Hill equation (see Methods); the listed S.D.
was determined from the curve fitting.
—IC50 values were determined in cells with internal solutions containing either 0 or 4 mM MgATP (block was very similar in these conditions).
https://doi.org/10.1371/journal.pone.0191225.t001
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To determine whether HC-070 could also block heteromeric channels, we assessed inhibi-
tion when TRPC1 was coexpressed with TRPC4 or TRPC5. Currents arising from TRPC1/
TRPC5 heteromers were distinguished by their distinct current-voltage relationship, which
lacks the dual-rectification characteristic of TRPC5 homomultimers [5]. HC-070 blocked
M2R-activated human TRPC1/TRPC4 channels with an IC50 of 1.3 nM and La
3+- and
M1R-activated human TRPC1/5 channels with an IC50s of 1.4 nM and 4.4 nM, respectively
(Table 1). We did not test TRPC1 expressed on its own, as we do not observe a current when
the clone is transfected independently of other TRPC family members, consistent with previ-
ous reports [5, 18, 19]. Whether HC-070 would inhibit TRPC1 when heteromultimerized with
other channels is not known. Overall, these IC50 values are similar to those observed with HC-
608 under identical testing conditions (Table 1, S1 Table).
HC-070 also reversibly blocked lanthanum-activated mouse TRPC5 (mTRPC5) current
(Fig 2 panels A and B) with an IC50 of 0.55 nM (Fig 2 panel C and Table 1). A representative
current-voltage relationship in the presence and absence of blocker is shown in Fig 2 panel B.
Fig 2. HC-070 inhibition of heterologously expressed mouse TRPC4 and TRPC5 channels. (A) Average currents at
-80 mV (filled circles) and +80 mV (open squares) during the application of varying concentrations of HC-070 (blue
bars). The TRPC5 current was activated by application of 80 μM lanthanum chloride (LaCl3) (gray bar), and 50 μM
2-aminoethyl-diphenyl-borinate (2-APB) (red bar) was used to completely block the TRPC5 current. Dotted lines
depict the estimated unblocked current, to account for channel rundown (see Methods). (B) TRPC5 current-voltage
curves recorded at the times in A shown by lower case letters (a, b, c). The steps at ±80 mV flanking the ramp, used to
calculate the averages in A, are not shown. (C) Dose-response curves of TRPC4 and TRPC5 channel inhibition by HC-
070. Symbols are the average % inhibition recorded from 3–13 cells; error bars are the standard error of the mean
(SEM; in some cases smaller than the symbol). Solid lines are fits of the Hill equation to the points. Mouse TRPC5
channels activated by 80 μM LaCl3 are shown by filled circles (fit parameters IC50 = 0.52 nM, Hill coefficient = 1.31).
Mouse TRPC4 (mTRPC4) channels activated by carbachol stimulation of human muscarinic 2 receptor (M2R) are
shown in crosses (fit parameters IC50 = 1.8 nM, Hill coefficient = 1.27), and mTRPC5 channels activated by carbachol
stimulation of the human muscarinic type 1 (M1R) is shown in open squares (fit parameters IC50 = 3.4 nM, Hill
coefficient = 0.91).
https://doi.org/10.1371/journal.pone.0191225.g002
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The slightly greater potency of HC-070 block of La3+-activated versus carbachol-activated
TRPC5 channels might result from different extents of channel activation caused by the two
stimuli we used, or differential allosteric coupling between activation mechanisms and com-
pound binding site, among other possibilities. Similar dependence of antagonist potency on
the method of activation has been reported for other TRP channels [20, 21]. Future work will
be needed to detail how HC-070 inhibits TRPC5 channels.
Since in vivo TRPC currents are likely to be activated by receptor stimulation, we assessed
the ability of HC-070 to affect currents elicited by carbachol stimulation of the muscarinic
receptors. HC-070 inhibited human TRPC5 currents activated via M1R with an IC50 of 2.0
nM. hTRPC4 currents were activated by the M2R, because M2 produced a more robust cur-
rent than other receptors tested. HC-070 inhibited hTRPC4 currents with an IC50 of 0.49 nM
(Table 1). Similar values were observed with HC-608 (S1 Table). Despite variable run-down
across cells and conditions of activation, we saw very little impact on our IC50s with standard
deviations for all conditions tested less than 35%.
Because of our interest in conducting behavioral pharmacology experiments in mice, we also
assessed the potency of HC-070 on the murine versions of TRPC4 and TRPC5 when activated
by carbachol. Given the high homology of the mouse and human channels, as expected, HC-070
was also highly potent relative to the orthologs tested (Fig 2 panel C and Table 1). These results
indicate that HC-070 and HC-608 potently inhibit TRPC4 and TRPC5 currents in vitro.
A useful inhibitor requires high selectivity in addition to high potency. We first measured the
maximal solubility of HC-070 in Ringer’s solution using high performance liquid chromatogra-
phy (HPLC). The resulting value was 1.9 μM. Therefore, we used this as the maximal concentra-
tion tested in our in vitro patch clamp assays assessing selectivity. We investigated the ability of
HC-070 and HC-608 to inhibit the activity of a range of ion channels in whole-cell manual
patch clamp, representing some of the major families. These included: TRPC3, TRPC6, transient
receptor potential cation channel subfamily vanilloid member 1 (TRPV1), TRPV member 3
(TRPV3), transient receptor potential cation channel subfamily ankyrin member 1 (TRPA1),
transient receptor potential cation channel subfamily melastatin member 8 (TRPM8), potassium
voltage-gated channel subfamily A member 3 (Kv1.3), potassium voltage-gated channel subfam-
ily A member 5 (Kv1.5), potassium voltage-gated channel subfamily D member 3 (Kv4.3), potas-
sium voltage-gated channel subfamily Q member 1 (Kv7.1), L-type voltage gated calcium
channel (Cav1.2), sodium channel, voltage-gated, type II (Nav1.2), sodium channel, voltage-
gated type 9 (Nav1.7), sodium channel, voltage-gated, type 5 (Nav1.5) and potassium voltage-
gated channel subfamily H member 2 (hERG). In most cases, HC-070 at 1.9 μM inhibited 50%
or less, though TRPC3 was inhibited with an IC50 of 1.0 μM (S2 Table). This indicates that HC-
070 is at least 400-fold selective for human TRPC4 and TRPC5-containing channels compared
to the other channels examined. HC-608 showed a similar selectivity profile (S2 Table).
To probe the effects of HC-070 on other targets that might interfere with the interpretation
of in vivo efficacy experiments, we assessed its effects at 1 μM on a selection of physiologically
relevant receptors, enzymes, kinases, and transporters (see S3 Table, S1 Report). HC-070
showed less than 50% inhibition in all of the targets assayed, indicating the selectivity is at least
400-fold for human TRPC4 and TRPC5. HC-608 was similarly selective (S4 Table, S1 Report).
Although both compounds performed similarly in our in vitro characterization, we decided
to focus on HC-070 for subsequent in-depth investigation.
HC-070 reduces activity in the basolateral amygdala
CCK-4 administration causes increased feelings of fear and anxiety in humans and induces
behaviors indicative of fear and anxiety in rodents. Human functional magnetic resonance
HC-070, a TRPC4/5 inhibitor, ameliorates behaviors associated with anxiety and depression in mice
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imaging studies show the emotions induced by CCK-4 correlate with increases in activity in
the cortical and limbic brain regions including the amygdala [22], a brain region shown to
be overactive in patients with anxiety and mood disorders associated with negative bias (see
Discussion) [23–25]. Previous work has shown strong expression of TRPC4 and TRPC5 in the
basolateral amygdala and TRPC4 or TRPC5 null mice have reduced CCK-4 receptor-activated
slow, inward currents [7, 8].
We tested whether HC-070 application would prevent or reduce CCK-4 stimulated
increases in excitatory post synaptic current (EPSC) frequency recorded from basolateral
amygdala neurons (Fig 3). EPSCs were measured by whole-cell recordings made from basolat-
eral amygdala neurons in coronal slices cut from C57BL/6 mouse brains.
Slices were superfused with either 20 nM HC-070 (confirmed by LC/MS) or DMSO vehicle
for 5 min. CCK-4 (1 μM) was then applied in the continued presence of HC-070 or vehicle.
The number of spontaneous EPSC events (>50pA) was recorded for 10 minutes after CCK-4
addition, and is shown relative to the preceding 2 minute baseline (Fig 3 panel C). The basal
synaptic activity prior to CCK-4 addition measured from slices pretreated with HC-070 was
154±35 postsynaptic currents/minute (n = 8) whereas in vehicle treated slices it was 77±18
postsynaptic currents/minute (n = 8).
CCK-4 (1 μM) substantially increased the mean number of postsynaptic currents recorded
compared to slices treated with vehicle (Fig 3 panel A), although the variability was high.
Fig 3. HC-070 attenuates CCK-4 induced EPSCs recorded from the basolateral amygdala in a slice preparation.
(A) Representative traces before and after CCK-4 application in the presence of vehicle. (B) Representative traces
before and after CCK-4 application in the presence or absence of HC-070. (C) Quantitation of the results (n = 8). HC-
070 was pre-incubated with the slice. CCK-4 was applied at the time indicated. Error bars represent the SEM (
p< 0.05, p<0.001, Tukey’s multiple comparisons test following two-way analysis of variance (ANOVA)). The
holding potential was -70 mV.
https://doi.org/10.1371/journal.pone.0191225.g003
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Application of 20 nM HC-070 led to pronounced attenuation of the CCK-4 related effect (Fig
3 panel B, quantified in Fig 3 panel C). While these EPSCs that we record are distinct from the
slow, excitatory currents previously reported [7,8], they are indicative of changes in excitability
resulting from increased presynaptic activity from neurons projecting to the recorded neuron.
Although we did not directly test the effect of HC-070 on native TRPC4 or TRPC5 channels in
neurons, our results show that treatment with HC-070 reduces CCK-4 evoked neuronal activ-
ity in the amygdala slices, by impacting the presynaptic inputs to the region.
As expected given the high nonspecific tissue binding of HC-070 (>99%; see section on
Pharmacokinetic properties) we found higher compound concentrations in the brain slices
(973 ± 173 nM, n = 9) compared to the concentration in the buffer. The buffer concentration of
20 nM, which we assume to reflect the free concentration of compound, should largely block
TRPC4- and TRPC5-containing channels. Given the observed selectivity profile, it is likely that
the observed compound effects at this concentration are TRPC4 and TRPC5-dependent.
Pharmacokinetic properties
Before testing HC-070 in behavioral assays, we sought to understand the PK properties of the
compound in the C57BL/6 mouse. For intravenous (IV) administration, HC-070 was formu-
lated as a solution at a final dose of 1 mg/kg. Plasma concentrations at various time points
were determined using liquid chromatography tandem mass spectroscopy (LC-MS/MS) tech-
nique (Fig 4 panel A). To assess if there were mouse strain differences, we repeated the phar-
macokinetic experiments in Swiss Webster mice (S2 Fig); the concentration-time profiles of
the two strains were quite similar.
The elimination half-life of HC-070 was 3.5 hours and 3.6 hours in C57BL/6 and Swiss
Webster mice, respectively. We observed a low clearance of 13 and 11 mL/min/kg for the two
strains, respectively. The volume of distribution at steady state (Vss) for HC-070 was 1.5 and
2.2 L/kg in C57BL/6 and Swiss Webster mice, respectively. This pharmacokinetic parameter is
the apparent volume of plasma required to account for all the drug in the body. A value larger
than the volume of body water (ca. 0.7 L/kg), as measured for HC-070, indicates that the com-
pound distributes readily into tissue.
For oral gavage dosing, HC-070 was formulated as a simple suspension in 0.5% methyl cel-
lulose. The oral dose of 10 mg/kg achieved its maximal plasma concentration at 1 hour in both
strains, indicating relatively rapid absorption (Fig 4 panel B and S2 Fig panel B). The elimina-
tion half-life of the compound was 3.3 and 2.7 hours in non-fasted C57BL/6 and Swiss Webster
mice, respectively. Comparing the HC-070 area under the curve when administered orally ver-
sus intravenously, the oral bioavailability was between 13 and 23%. The PK properties in the
two strains are summarized in Fig 4 panel C and S2 Fig panel C.
Since the properties observed were so similar between the two strains of mice tested, we
did not perform full pharmacokinetic studies in the other mouse strains used. Rather, we took
plasma levels from animals at the end of the study where possible and compared them with the
expected values.
Because the proposed site of action for a TRPC4/5 antagonist is the brain, we compared the
compound levels in brain with those found in plasma two hours after dosing. Following IV (1
mg/kg) administration, 339 ± 66 nmol/L HC-070 were present in plasma while 299 ± 11 nmol/
kg compound were detectable in brain. Brain and plasma exposures, after a 10 mg/kg po dose
were similar after oral administration, namely 583 ± 108 nmol/L plasma and 525 ± 72 nmol/kg
brain tissue (summarized Fig 4 panel D). Due to the high PPB of HC-070 (99.6%) we also mea-
sured the unbound fraction in brain; this was 0.0028 ± 0.0002 at a HC-070 concentration of
1 μM. While the above measured total brain concentration of 525 nmol/kg is high, the
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pharmacologically-relevant, unbound brain concentrations was only 1.5 nmol/kg. These
observations confirmed that HC-070 has ready access to the brain and guided dose selection
for in vivo testing in behavioral models, allowing focus on levels that should yield unbound
brain exposure within 10-fold of the unbound IC50 for TRPC4 and TRPC5.
In vivo efficacy in tests and models of anxiety and fear
Elevated plus maze. The EPM test is an in vivo test widely used to assess anxiolytic activ-
ity. In this test, a conflict (the state of anxiety) is established between the animal’s innate moti-
vations to seek safety (closed arms) and to explore a relatively unsafe environment (open
arms). Anxiolytic manipulations reduce the motivation to seek safety, thus increasing entry
into, and time spent, on the open arms. Anxiogenic manipulations decrease open arm entries.
One such anxiogenic manipulation is activation of the CCKB receptor [26]. Since HC-070 dra-
matically reduces CCK-4 dependent synaptic activity in brain slices, we tested the effects of the
compound on CCK-4 induced anxiety in the mouse. Conditions were modified from the stan-
dard EPM test by reducing light intensity in order to reduce basal anxiety, thus allowing detec-
tion of a CCK-4 anxiogenic effect. Systemic administration of 0.3 mg/kg (intraperitoneal, IP)
CCK-4 decreased the percent of entries into the open arms as expected [26]. This effect was
Fig 4. Pharmacokinetic properties of HC-070. PK profiles of HC-070 after intravenous (A) and oral (B)
administration in C57BL/6 mice. Plasma concentrations were determined by LC-MS/MS. Points represent the
individual concentrations at the times indicated. Lines represent mean exposure (n = 12 mice/arm, n = 3 data points
per time point). (C) Summary of PK properties. CL = clearance; Vss = volume of distribution at steady state; MRTdisp =
mean residence time of drug molecules after intravascular administration; T1/2 = half-life. (D) Plasma and brain
concentrations measured 2 hours after intravenous or oral administration of 1 or 10 mg/kg HC-070, respectively. CPL
= concentration in plasma, CBR = concentration in brain, KP,BR = partitioning coefficient between brain and plasma.
https://doi.org/10.1371/journal.pone.0191225.g004
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completely blocked by oral administration of HC-070 at 1 mg/kg (Fig 5). HC-070 only affected
mice with increased evoked anxiety (CCK-4). Animals treated with HC-070 in the absence of
CCK-4 showed no changes in anxiety under these low anxiety conditions. Average HC-070
plasma levels were in line with expected values.
To test the impact of HC-070 in a standard EPM (more light/high anxiety), the number of
open arm entries was recorded for 5 minutes, 1 hour post oral administration of vehicle or 0.3,
1 or 3 mg/kg HC-070, or 30 minutes post IP administration of 1.5 mg/kg diazepam, the posi-
tive control. Administration of HC-070 increased open arm entries compared to vehicle in a
dose dependent manner with the 3 mg/kg dose achieving significance (Fig 6 panel A, p<0.01,
Dunnett’s post-hoc test for significance following one-way ANOVA), consistent with previous
reports from TRPC4 and TRPC5 null mice [7, 8]. The anxiolytic diazepam significantly
increased the total number of open arm entries to a similar degree as 3 mg/kg HC-070 (Fig 6
panel A, p<0.01, t-test). The sample size of animals per group was uneven because the small
number of mice that jumped or fell off the EPM during the experiment were excluded. Com-
pound exposures were again found to be in the expected range (Fig 6 panel B). The unbound
brain concentration at 3 mg/kg, calculated from the total brain concentrations and the fraction
unbound in brain, was 1.7 nM.
Chronic social defeat and fear learning and memory. Uncontrollable stressful events
are known to be etiological factors leading to generalized changes in emotion and increased
responsiveness to neutral stimuli predicting aversive stimuli in patients. This can be tested in a
Fig 5. HC-070 decreases anxiety after CCK-4 treatment in an EPM. Treatment with CCK-4 decreased the percent of
open arm entries (p < 0.05, t-test), as expected. Administering HC-070 orally at 1 mg/kg prevented the reduction in
open arm entries induced by CCK-4 (p<0.05, t-test, n = 12/group). HC-070 exerted no effect on percent of open arm
entries in the absence of CCK-4. Each animal is represented on the graph (circles) and the horizontal lines represent
the mean. The actual exposures of HC-070 at the time the mice were sacrificed were 262±63 and 301±81nM for the
CCK-4 + HC-070 and VEH + HC-070 groups, respectively.
https://doi.org/10.1371/journal.pone.0191225.g005
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model of chronic social stress-induced fear hyperreactivity in mice, where fear was measured
using Pavlovian conditioning [27].
Firstly, we studied HC-070 effects in the fear learning and memory test in otherwise non-
manipulated mice (S3 Fig). This test comprises placing the animal in an arena (context) and
pairing a tone, the conditioned stimulus (CS), with mild electroshocks, the unconditioned
stimulus (US), and measuring fear “freezing” (complete immobility) to the CS. On the first
test day baseline freezing levels were measured by placing mice in the arena without CS or
US, and without drug; all mice showed low baseline freezing (S3 Fig panel A). On the next
day, mice were administered vehicle or HC-070 at 1 or 3 mg/kg orally and 2 hours later
underwent CS-US fear conditioning. The compound did not affect fear learning, with each
group acquiring increased freezing to the CS across successive CS-US trials (Trial-block
main effect p<0.0005, S3 Fig panel B). On the next day, mice were administered HC-070 at
the same dose and after 2 hours were placed back in the same context in which conditioning
took place. There was no drug effect on fear memory expression to the context (p = 0.82
Fig 6. HC-070 decreases anxiety in a standard EPM. (A) Mice were administered vehicle or 0.3, 1 or 3 mg/kg HC-
070 orally 60 minutes prior to EPM. The positive control, 1.5 mg/kg diazepam, was administered IP 30 minutes prior
to testing. At 3 mg/kg, HC-070 significantly increased the number of open arm entries compared to the oral control
( p<0.01, Dunnett’s post-hoc test following one-way ANOVA). The positive control, 1.5 mg/kg diazepam, also
increased open arm entries ( p<0.05, t-test). Animals that jumped or fell off the EPM during the test were excluded,
such that the sample size (n) differed between groups. Each animal is shown on the graph (circles) and the horizontal
lines represent the mean. (B) Average plasma and brain exposures from satellite animals dosed with 0.3, 1, or 3 mg/kg
HC-070, 60 minutes post dosing. Error bars show standard deviation.
https://doi.org/10.1371/journal.pone.0191225.g006
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S3 Fig panel C). Immediately thereafter, the CS was presented repeatedly: there was no drug
effect on fear memory expression to the CS (p = 0.27 S3 Fig panel D), with mice in each
group showing a high and similar level of freezing to the first CS followed by a consistent
decrease across CS trials (p<0.0005).
Chronic social defeat (CSD) involves exposing mice to prolonged social stress, and
increases fear learning and memory [28]. In this paradigm, a smaller (CSD) C57BL/6 mouse
is housed next to a larger, dominant CD-1 mouse, separated by a Plexiglas barrier permeable
to sensory cues. Once daily for 15 days, for a brief period of time the submissive mouse is
introduced to the aggressor mouse. Following this period of social stress, the CSD mice and
control mice were studied in the fear learning and memory test, in which time spent freezing
provides a measure of fear learning and subsequent fear memory. On day 16, the mice were
placed in the arena to test baseline freezing levels, and there was a trend to increased freezing
in CSD compared with control mice (Fig 7 panel A). On day 17, mice underwent CS-US fear
conditioning; relative to controls, CSD mice showed increased CS-US fear learning (Fig 7
panel B), as expected based on previous studies [28]. Immediately after this experience, both
CSD and control mice were administered vehicle or HC-070 at 1 mg/kg PO. The next day,
mice received the same dose of HC-070 (vehicle or 1 mg/kg) and 1 hour later were placed
back in the arena. Firstly, mice underwent a test of context fear memory, that is, they were
placed in the arena without the CS or US. TRPC4/5 inhibition reduced the relatively high
context fear memory in CSD mice (Fig 7 panel C). Second, mice underwent a test of CS
memory, with the CS presented during repeated trials and separated by inter-trial intervals.
TRPC4/5 inhibition reduced the relatively high CS fear memory in CSD mice, with the
duration of freezing decreasing more substantially across successive CS presentations in
CSD-HC-070 mice than in CSD-vehicle mice (Fig 7 panel D). Also in the intervals between
CS presentations, CSD-vehicle mice showed high levels of freezing whereas freezing in
CSD-HC-070 mice was ameliorated to the level of control mice (Fig 7 panel E). These results
indicate that TRPC4/5 inhibition acts to reverse the CSD stress effect of increased consolida-
tion/expression of the fear memory of the discrete CS and the context. The time course of
the effects suggests that the primary effect of TRPC4/5 inhibition is to increase the extinction
of these fear memories (Fig 7 panels D-E).
Marble burying test. In addition to using bedding material to bury noxious materials,
rodents also bury harmless objects such as rat chow pellets and glass marbles. It has been pro-
posed that marble burying shares features of compulsive behavior [29]. Selective serotonin-
reuptake inhibitors, which are used clinically in the treatment of patients with obsessive com-
pulsive disorder, reduce the number of marbles buried [29]. Because there are features of anxi-
ety in this model, we probed the effect of inhibiting TRPC4 and TRPC5.
We treated female C57BL/6 mice with vehicle or 1, 3 or 10 mg/kg HC-070 PO 60 minutes
prior to the marble burying test. The positive control, 10 mg/kg zimelidine, was administered
IP 45 minutes prior to testing. The number of buried marbles was recorded after 30 minutes
by an observer blind to compound treatment. At each dose, HC-070 decreased the total num-
ber of marbles buried by more than 50% compared to vehicle (Fig 8 panel A, p<0.05, Dun-
nett’s post-hoc test for significance following one-way ANOVA). Zimelidine also significantly
reduced the total number of marbles buried, as expected (Fig 8 panel A, p<0.05, t-test). Com-
pound exposures were consistent with other studies (Fig 8 panel B).
One interesting feature of this test that distinguishes it from others is that efficacy is based
on the animal decreasing its activity i.e. reduced marble burying. This is distinct from tests of
anxiety such as the EPM and tests of anti-depressant activity such as the forced swim test
where an increase in activity provides the positive readout.
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Fig 7. Effects of HC-070 on CSD-induced fear hyper-reactivity. HC-070 reduces the increased capacity for fear memory in
mice exposed to chronic social stress on days 1–15. (A) Day 16: Without drug administration, when placed in a relatively
unfamiliar arena (context) without tone or electroshock, mice that had been exposed to chronic social defeat (CSD) tended to
show more freezing—a fear behavior—than did control mice (CON). (B) Day 17: Without drug administration, mice were placed
back in the same context and exposed to 6 pairings of a 20 s tone conditioned stimulus (CS) that announced a 2 s electroshock
unconditioned stimulus (US). CSD mice acquired more freezing to the CS than did CON mice. The left panel presents the fear
learning curve using the average freezing during CS-US trials 1–2, 3–4 and 5–6, and the right panel presents the average freezing
across all six CS-US trials. Immediately after this CS-US conditioning session, CSD and CON mice received either vehicle or 1
mg/kg HC-070 orally. (C) Day 18: Mice received vehicle or 1 mg/kg HC-070 orally and 1 hour later were placed in the same
context in which CS-US conditioning took place the previous day, and a 21-min test of context fear memory was conducted, i.e.
in the absence of the CS (and US). The left panel presents the context-fear expression curve using the average freezing per 3-min
block. The right panel presents the average context-fear expression across all 21 min. HC-070 significantly reduced the context
fear memory in CSD mice, as indicated by these mice showing freezing levels similar to those of CON mice and lower than those
of CSD-VEH mice. (D) Day 18: Immediately after the context fear memory test, the tone-CS fear memory test was conducted,
comprising 12 trials of 30-s CS separated by 90-s inter-trial intervals. The fear expression curve to the CS is presented using the
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In vivo efficacy in tests of anti-depressant activity
HC-070 also demonstrated significant effects in tests known to be sensitive to anti-depressants.
One commonly used test is the tail suspension test. NMRI mice are suspended by their tails
and the amount of time they are active versus remaining immobile is recorded. HC-070 was
delivered orally at 0.3, 1.0, 3.0 or 10 mg/kg 60 minutes prior to assessment. Compound
average freezing per pair of consecutive CS trials. HC-070 tended to reduce the CS fear memory in CSD mice, as indicated by the
increased rate at which their freezing level during the CS attenuated compared with CSD-VEH mice, i.e. faster extinction
learning. (E) Day 18: In the tone CS memory test presented in (D), freezing was also measured in the inter-trial intervals (ITIs)
between CS presentations. The left panel presents the fear expression curve in ITIs between CSs using the average freezing per
pair of consecutive ITIs. The right panel presents the average freezing across all 12 ITIs. Here also, HC-070 reduced fear memory
in CSD mice, as indicated by the increased rate at which their freezing level during the ITIs attenuated compared with CSD-VEH
mice, i.e. faster extinction learning.
https://doi.org/10.1371/journal.pone.0191225.g007
Fig 8. HC-070 reduces marble burying behavior. (A) Mice were administered vehicle or 1, 3 or 10 mg/kg HC-070
orally, 60 minutes prior to testing. The positive control, 10 mg/kg zimelidine, was administered IP 45 minutes prior to
testing. At 1, 3, and 10 mg/kg, HC-070 significantly decreased the number of buried marbles compared to vehicle (p
<0.05 , p<0.01, Dunnett’s post-hoc test following one-way ANOVA, n = 10/group). Zimelidine also decreased the
number of buried marbles (p < 0.05, t-test, n = 10/group). Each animal is represented on the graph and the horizontal
lines represent the mean. (B) Average plasma exposures from animals that completed the test. Error bars are the
standard deviation.
https://doi.org/10.1371/journal.pone.0191225.g008
HC-070, a TRPC4/5 inhibitor, ameliorates behaviors associated with anxiety and depression in mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0191225 January 31, 2018 14 / 32
treatment reduced the amount of time animals were immobile at all doses (Fig 9 panel A,
p<0.05, Dunnett’s post-hoc test for significance following one-way ANOVA). The effect size
was similar to that observed with the positive control, the tricyclic anti-depressant, desipra-
mine (Fig 9 panel A, p<0.05, t-test). Plasma levels were as expected in test animals (Fig 9
panel B).
Locomotor activity in transparent square cages equipped with 2 light barrier systems was
not impacted by these doses of HC-070 (two-way ANOVA, followed by a Tukey’s multiple
comparisons test; p>0.5) (Fig 9 panel C), suggesting that the effects observed were specific to
an acutely stressful situation. Phencyclidine (PCP), the positive control in the locomotor activ-
ity test, had the anticipated effect of decreasing activity (S4 Fig). Together, these data suggest
that HC-070 exerts a behavioral effect similar to that of anti-depressants in in the mouse tail
suspension test.
To extend these findings, we also examined the effects of HC-070 in the forced swim test
(FST) in CD-1 mice. In this test, mice are placed in a water-filled cylinder and the amount of
time they are mobile (swim, climb) versus the amount of time they are immobile is recorded.
The immobility recorded in this test can be reversed by all major classes of antidepressants
[30]. HC-070 at doses of 0.3, 1.0 or 3.0 mg/kg 60 minutes prior to testing reduced the immobil-
ity time (p<0.05, Dunnett’s post-hoc test for significance following one-way ANOVA, Fig 10
panel A). The positive control, the tricyclic anti-depressant imipramine (20 mg/kg, IP), also
decreased immobility time (p< 0.05 t-test, Fig 10 panel A) and to a similar magnitude to that
of 3 mg/kg HC-070. Plasma levels of HC-070 were as anticipated based on PK studies per-
formed in other strains of mice (Fig 10 panel B).
Since we could observe graded responses in the forced swim test, we used this paradigm to
probe the relationship between pharmacodynamic effects of HC-070 and pharmacokinetics.
To ensure the robustness and reproducibility of the response, we tested a second mouse strain
at a second site. Results between the two strains and sites were consistent and the efficacious
doses were similar, with 1 mg/kg exerting significant efficacy. Plotting the average effect on
immobility versus the average plasma exposure resulted in a sigmoidal curve with an IC50 cor-
responding to 58 nM (Fig 10 panel C), establishing a clear relationship between PK and PD in
the FST. When corrected for protein binding, this corresponds to an unbound plasma level of
0.23 nM and calculated free brain concentrations of 0.16 nM. These values are lower than the
IC50 values after receptor activation in the heterologous system for mouse TRPC5 (3.4 nM)
and mouse TRPC4 (1.8 nM). Observing biological effects at unbound levels below the IC50 is
not uncommon for ion channel targets [31–33].
Discussion
Our results provide strong evidence that acute inhibition of TRPC4 and TRPC5 with HC-070
reduces behavior associated with anxiety and depression in mouse models.
In brain slices, application of HC-070 dramatically reduces EPSC-frequency in the basolat-
eral amygdala stimulated by the panic inducing peptide, CCK-4. Which presynaptic neurons
within the network are the source of the observed change in activity was not investigated in
our experiments and remains to be determined. It is hypothesized that in patients with anxiety
and mood disorders an overactive amygdala is a major contributor to attentional bias to nega-
tive stimuli, pessimistic thoughts, and anxiety [23–25]. In their recently published Research
Domain Criteria (RDoC) framework, the NIMH suggests that changed cortico-limbic reactiv-
ity is a central feature of the symptoms associated with negative emotional processing such as
anxiety, rumination, and depressed mood [34]. Normalization of the hyperactive circuits may
therefore improve emotional control and reduce these negative valence systems. Behaviorally,
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Fig 9. HC-070 reduces time of immobility in a tail suspension test but does not impact locomotor activity. (A)
Mice were administered vehicle or 0.3, 1, 3 or 10 mg/kg HC-070 PO 60 minutes prior to testing. The positive control, 8
mg/kg desipramine, was also administered orally. All doses of HC-070 reduced the time of immobility (p<0.05
, p<0.01, p< 0.001  Dunnett’s post-hoc test following one-way ANOVA, n = 13–16 group), as did desipramine
(p<0.0001, t-test) Each animal is shown on the graph and the horizontal lines represent the mean. (B) Associated
exposures. Error bars are the standard deviation. (C) Locomotor activity was not impacted. After 90 minutes of
habituation to an activity chamber, mice were administered vehicle or 0.1, 3 or 10 mg/kg HC-070 PO. Activity was
recorded for another 60 minutes. There was no effect of dose (2-way ANOVA followed by a Tukey’s multiple
comparison’s test, p>0.5 for all treatments; n = 8/group).
https://doi.org/10.1371/journal.pone.0191225.g009
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Fig 10. HC-070 reduces time spent immobile in the FST in a dose and exposure-dependent fashion. (A) HC-070
reduces the time spent immobile in the forced swim test to a similar degree as the positive control. Mice were
administered vehicle, or 0.3, 1 or 3 mg/kg HC-070 PO, 60 minutes prior to FST. The positive control, imipramine, was
administered IP at 20 mg/kg 45 minutes prior to testing. At all doses tested, HC-070 significantly decreased the time
mice spent immobile (p<0.01, p<0.01, Dunnett’s post-hoc test following one-way ANOVA, n = 12/group). The
positive control, 20 mg/kg imipramine, also decreased immobility (p< 0.001, t-test, n = 12/group). (C) PK-PD
modelling of the HC-070 concentration-effect from 3 separate forced swim studies. The included studies had the
following treatment arms: vehicle, 0.3, 1, 3 mg/kg dose of HC-070 in male CD-1 mice, n = 12 per group (also shown in
A); a vehicle and 1 mg/kg dose of HC-070 in male C57BL/6 mice (n = 11 per group); and a vehicle, 0.1, 0.3, 1 mg/kg
dose of HC-070 in male C57/BL6 (n = 12 per group). Vehicle and HC-070 were administered PO, 60 min prior to
testing. Immobility was normalized to the vehicle control of each individual study. Error bars are SEM.
https://doi.org/10.1371/journal.pone.0191225.g010
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HC-070 increases exploratory behaviors in EPM after CCK-4 exposure. It is possible that HC-
070 exerts its behavioral effects, at least in part, by reducing excitability of the amygdala. Other
brain regions where TRPC4 and TRPC5 are expressed may also be important in mediating the
behavioral effects of HC-070.
Pharmacokinetic studies reveal that oral dosing of HC-070 as a simple methylcellulose sus-
pension results in plasma and brain exposures compatible with efficacy testing. HC-070 has a
high non-specific binding to tissue, thus total plasma and tissue concentrations are not reflec-
tive of the pharmacologically relevant exposure, and unbound plasma and unbound brain
concentrations are more relevant for in vivo efficacy. As is observed with many ion channel
inhibitors, free concentrations below the IC50 already result in efficacy. Overall, the unbound
plasma and brain concentration range at which we observe efficacy are within 10-fold of the
IC50 for TRPC4 and 5 determined in vitro.
In the behaving mouse, inhibition of TRPC4 and TRPC5 results in anxiolytic disinhibition
of exploration in a CCK-anxiety model, decreased marble burying, increased activity in tests
of antidepressant efficacy, and amelioration of hyper-fear memory in socially stressed mice.
The latter effect is largely due to acceleration of memory extinction for the aversive condi-
tioned stimulus by HC-070. As amygdala activity is also a known regulator of emotional pro-
cessing and stress induced by CSD [27, 28], we speculate that reduced amygdala activity may
also underlie some of HC-070 efficacy in the behavioral effects observed.
Consistent with work in null mice [7, 8], inhibition of TRPC4 and TRPC5 did not impact
fear learning or fear memory in non-manipulated (control) mice. Blocking the channels also
had no generalized effect on locomotion, suggesting that HC-070 is more likely to reduce the
negative valence systems than impact arousal or psychomotor function.
Whilst the present data demonstrate that HC-070 is a potent and selective blocker of
TRPC4 and TRPC5 and a modulator of neuronal activity and anxious behavior, some ques-
tions remain regarding the specific neuropharmacological effects of HC-070. The methods of
activation are different for the two channels and multiple pathways are likely to contribute to
channel activation in vivo. In our studies, we have not investigated whether or not HC-070
preferentially inhibits TRPC4 or TRPC5 or whether it inhibits both equably.
In a native system, we show that HC-070 reduces CCK-4 stimulated activity in the basolat-
eral amygdala, a region of high TRPC4 and TRPC5 expression that is essential in emotional
neural circuitry. Nonetheless, future studies will be needed to determine whether additional
brain regions are important in mediating the behavioral effects of HC-070. Furthermore, it
will be important to address which cells types express TRPC4 and/or TRPC5 channels, and
which G-protein coupled receptors within those cells activate them and finally how exactly
HC-070 inhibits TRPC4 and TRPC5 dependent currents in neurons.
Taken together, the data presented provide a strong rationale for considering TRPC4 and
TRPC5 as targets for the alleviation of symptoms associated with human psychiatric disorders.
Given the profile observed, conditions such as major depressive disorder, obsessive-compul-
sive disorder, post-traumatic stress disorder, and generalized anxiety disorder could be amena-
ble to treatment.
The mechanism of action, TRPC4 and TRPC5 inhibition, is distinct from current therapeu-
tics and has the potential to impact multiple transmitter systems. The channels are down-
stream of numerous signaling pathways including any GPCRs that signal via G-alpha q as well
as Gi and Go [5, 6, 10, 11]. In addition, activity of TRPC5 homomultimers is strongly potenti-
ated by calcium [35], linking the activity of the channel to several other signaling events. Being
mechanistically distinct, antagonists to TRPC4 and TRPC5 channels could have potential to
provide relief to patients who do not respond to current therapies. The precise neurotransmit-
ter systems and circuitry impacted by inhibition of TRPC4 and TRPC5 await further study.
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Such work will be useful in identifying relevant symptoms and patient populations most likely
to respond to this mechanism of action.
This contribution to the understanding of the biological role of these channels was made
possible by the invention and characterization of the highly potent and selective chemical
antagonist to TRPC4 and TRPC5 that we call HC-070. HC-070 shows all the properties of a
high-quality small molecule inhibitor. We believe this compound represents an important lead
molecule with which to progress the understanding of TRPC channel biology. To enable these
efforts, we are making HC-070 available to the research community free of charge. Interested
parties should direct inquiries to: Christian.Eickmeier@Boehringer-Ingelheim.com.
Materials and methods
Cells
The cDNAs for various full-length ion channels were subcloned into pcDNA5/TO. Stable
clonal T-REx-293 (Invitrogen) lines were selected after transfection with the plasmid of inter-
est with 100 μg/mL hygromycin and 5 μg/mL blasticidin. Some cell lines stably expressed the
human muscarinic type 1 or 2 receptor (M1R and M2R) under G418 selection (1 mg/mL).
Cells were maintained according to manufacturer’s instructions. TRPC4 channels were the
TRPC4beta isoform. Human hERG channels and human Kv1.3 channels were constitutively
expressed in Chinese hamster ovary cell stable lines. CHO cells were cultured in DMEM/F-12
(1:1) supplemented with 10% FCS, 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM gluta-
mine. Inducible cell lines were treated with tetracycline and plated on glass coverslips 18–24
hours before patch clamping.
High-throughput screening
Cells stably expressing the human TRPC5 cDNA were plated at a density of ~35,000 cells/well
in 384 well black wall clear bottom CellBind plates (Corning). Cells were induced with 1 μg/ml
tetracycline, and allowed to grow for 20–30 hours. Cells were loaded with 25 μL of either 4 μM
Fura-2/AM or 0.5 μM Fluo4/AM (Invitrogen) in Hank’s Balanced Salt Solution (HBSS; 0.185
g/L D-glucose, 0.9767 g/L MgS04 (anhydrous), 0.4 g/L KCl, 0.06 g/L KH2PO4 (anhydrous),
0.35 g/L NaHCO3, 8.0 g/L NaCl, and 0.04788 g/L Na2HPO4 (anhydrous); pH 7.4) supple-
mented with 0.02% Pluronic acid for ~1 hour in the dark at room temperature. The dye was
removed and replaced with 25 μl HBSS. Following recovery from loading, cells were assayed
using the Hamamatsu FDSS 6000 system, which permitted illumination alternately at 340 nm
and 380 nm for Fura-2 experiments, or at 485 nm for Fluo-4 experiments. Images were
acquired at a rate of ~0.2 Hz. Baseline fluorescence of the plates was measured followed by
addition of 26 μl of 50 μM test compound to each well. Fluorescence was monitored for 2 min-
utes then 13 μl high- Ca2+ Ringer’s solution (62.55 mM NaCl, 4.5 mM KCl, 62 mM CaCl2, 1
mM MgCl2, 10 mM HEPES, 10 mM Glucose pH 7.4) was added resulting in a final concentra-
tion of 14 mM Ca2+ and 10 μM test compound. Different concentrations of calcium were
tested during assay development, and although lower concentrations of calcium elicited
responses, 14 mM was chosen as the final concentration as it gave the best screening window.
Data were collected for ~3 minutes following addition of high Ca2+ Ringer. Positive and nega-
tive control wells were included on each plate consisting of 200 μM of the promiscuous blocker
2-APB or HBSS alone, respectively.
For fluorescent IC50 determination the test compounds were serially diluted to concentra-
tions of: 2.5 μM, 1.25 μM, 625 nM, 312.5 nM, 156.25 nM, 78.13 nM, 39.06 nM, 19.53 nM, 9.77
nM, 4.88 nM, 2.44 nM, 1.22 nM, 610 pM, 305 pM, 153 pM, 76 pM, 38 pM, 19 pM, 10 pM, 5
pM, and 2 pM. 8 replicates of the serial dilution were performed. The fluorometric assay was
HC-070, a TRPC4/5 inhibitor, ameliorates behaviors associated with anxiety and depression in mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0191225 January 31, 2018 19 / 32
then performed as above so that the following final compound concentrations were achieved
in the assays: 1 μM, 500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM, 15.63 nM, 7.81 nM, 3.91
nM, 1.95 nM, 977 pM, 488 pM, 244 pM, 122 pM, 61 pM, 31 pM, 15 pM, 8 pM, 4 pM, 2 pM,
and 1 pM. To construct concentration response curves the fluorescence intensity for each well
at each time point was divided by the initial fluorescence intensity in that well. The response to
agonist was determined by averaging the last four time points except the final time point. The
percent inhibition was determined by comparing the average agonist response in the test wells
with the average agonist response in the positive and negative control wells.
Screening of TRPC4 was performed essentially as above with the following differences: cells
stably expressing human TRPC4 and the muscarinic acetylcholine receptor type 1 (M1) were
used in the assay. The cells were activated by adding carbachol diluted in high calcium Ringer’s
to a final concentration of 7 μM.
Electrophysiology
Cells expressing the channel of interest were voltage clamped with an Axopatch 200B or 700B
controlled by pClamp 10 (Molecular Devices). Pipettes were 1.2–3 Mohm resistance, and 60–
75% of the series resistance was compensated. Currents were filtered at 2 kHz, and acquired at
10 kHz with a Digidata 1320 or 1321. The typical voltage protocol for TRP channel currents
consisted of a holding potential of -40 mV, a 20 ms step to -120 mV, followed by a 400 ms
ramp to +100 mV. These ramps were preceded by a 100 ms step to -80 mV, and immediately
followed by a 15 ms step to +80 mV. In some recordings, the ramp was 400 ms from -80 to
+80 mV (with 40 ms at ±80 mV, before and after the ramp). Ramps were applied every 5 s, and
currents were averaged at ±80 mV, as the average of 5–20 ms at the end of the steps flanking
the ramp (when any residual capacity current was finished flowing). Liquid junction potentials
were not corrected.
The standard bath solution was Ringer’s solution (in mM) 145 NaCl, 4.5 KCl, 2 CaCl2, 1
MgCl2, 10 HEPES, 10 glucose, pH 7.4 (NaOH). 80 μM LaCl3 or 20 μM carbachol were added
to this solution to activate TRPC5; 10 μM carbachol was used for TRPC4 recordings (the
method of channel activation is detailed in Table 1). Cellular TRPC4 channels were not acti-
vated by the addition of lanthanum alone, and stimulation with carbachol and M1R activation
yielded variable currents that desensitized rapidly. M2R stimulation via carbachol gave much
more robust and long-lasting currents, so TRPC4 channel assays were performed using this
activation method. The internal solution for TRPC4 and TRPC5 recordings contained (in
mM) 140 Cs-aspartate, 1.91 CaCl2, 2.27 MgCl2, 10 HEDTA, 10 HEPES, pH 7.2 (with CsOH).
The predicted free [Ca2+] of this solution is 1.4 μM. The internal solution for receptor-acti-
vated currents contained 0.3 mM Na-GTP and 1–4 mM ATP. All other components were the
same. External solutions at the cell were switched using a gravity fed, local perfusion system.
For most ion channel selectivity experiments (S2 Table), the internal solution was K-aspar-
tate based for potassium channel recordings and Cs-aspartate for all others (in mM, 140 K-
aspartate or Cs-aspartate, 1.91 CaCl2, 2.27 MgCl2, 10 EGTA, 10 HEPES, pH 7.2 with KOH or
CsOH). The predicted free [Ca2+] of this solution was 50 nM. The standard external solution
was Ringer’s except for TRPA1, where we used a Ca2+-free Ringer’s (145 NaCl, 4.5 KCl, 3
MgCl2, 1 EGTA, 10 HEPES, 10 glucose, pH 7.4 with NaOH).
The standard bath solution for patch clamp experiments with KV7.1/minK expressing cells
was (in mM): 140 NaCl, 4.0 KCl, 1.0 MgCl2, 1.8 CaCl2, 10 glucose, 10 HEPES (pH 7.4 with
NaOH). The intracellular solution was (in mM): 120 K-aspartate, 5.0 EGTA, 5.0 HEPES, 2.0
Mg2-ATP, 0.3 Na3-GTP, 14.0 Na2-phosphocreatine, 50 U/mL creatine phosphokinase (pH 7.2
with KOH), 30 μM PMA (phorbol 12-myristate 13-acetate). Whole-cell recordings were made
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using an EPC-10 amplifier and PatchMaster software (HEKA, Lambrecht, Germany). The fol-
lowing voltage protocol was used: -80 mV (Vhold), 20 mV (2000 ms),-40 mV (500 ms), -120
mV (10 ms) (applied every 30 sec).
Patch clamp recordings of KV1.5 and KV4.3 were performed at bSys (Basel, Switzerland), as
follows: CHO cells stably expressing either KV1.5 or KV4.3/KChiP2 were voltage clamped at a
holding potential of -80 mV and test steps were applied to +40 mV (500 ms at 0.1 Hz for KV1.5
and 5000 ms at 0.05 Hz for KV4.3). The peak current during the step to +40 mV was analyzed.
IC50 measurements were made as follows: After seal formation, break-in, and the setting of
parameters for series resistance compensation, the current was activated as indicated in Fig 2
and Table 1, as well as S1 and S2 Tables. In some cases, the current reached a steady-state that
remained stable, at which point the test compound application began. In other cases, the cur-
rent reached a peak and then began to decrease, reflecting either desensitization and/or chan-
nel run-down. For these cases, we waited to apply test compound until the current decrease
slowed down (which varied from cell to cell). After the current reached a new steady-state fol-
lowing test compound addition, we applied compound-free external solution to determine the
extent of current recovery. In some recordings, recovery was preceded by application of con-
trol blocker (to determine the amount of leak current) or by a higher concentration of test
compound (e.g., Fig 2 panel A). Throughout the experiment, we monitored the shape of the
currents during the test pulse or ramp.
To calculate the percent block, the current remaining after compound addition was mea-
sured and compared to the predicted unblocked current (after leak was subtracted from both).
This was predicted as the linear interpolation of the current amplitudes in control external
solution immediately before compound addition and after compound washout (Fig 2 panel
A). This process, when updated with multiple recovery periods throughout the recording,
accounts for some of the cell to cell variability in run-down.
Typically 3–4 concentrations of test compound were applied to a single cell. The percent
blocks from individual cells were fitted with the Hill equation (using Levenberg-Marquardt
algorithm, base and max block set to 0 and 100%, respectively, IC50 and Hill slope allowed to
vary). The resulting IC50s were then averaged.
Selectivity profiling
All other selectivity work was performed at CEREP, as described in S1 and S2 Reports. Data
are reported as the per cent inhibition at 1 μM.
Solubility assay
Solubility in Normal Ringer Solution was determined by dissolving a standard range of vol-
umes of 10 mM DMSO stock of HC-070 in Normal Ringer’s Solution at room temperature.
Following vortex and incubation for 40 minutes at room temperature, solutions were filtered,
quenched, and analyzed by liquid chromatography. Solubility limits were determined by com-
parison to a standard curve generated by dissolving compound in acetonitrile.
Slice recordings
Coronal brain slices (250 μm) containing the basolateral amygdala were prepared from male
C57BL/6 mice using a VT1200S vibratome (Leica). Slices were continuously superfused in
solution containing the following (in mM): 125 NaCl, 2.5 KCl, 1.8 CaCl2, 0.8 MgCl2, 1.3
NaH2PO4, 26 NaHCO3, 25 glucose and 0.5 Na- L-Lactate and equilibrated with 95% O2 and
5% CO2, pH 7.3–7.4, at 22–23˚C.
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Whole-cell recordings of postsynaptic currents were obtained from pyramidal neurons in
the basolateral amygdala under visual guidance (infrared optics) with an EPC-10 amplifier and
PatchMaster 2x73 software (HEKA Elektronik). In voltage-clamp experiments, the recording
patch electrodes (2.5–4 MΩ resistance) contained the following (in mM): 110 KCl, 10 NaCl, 1
MgCl2, 0.5 CaCl2, 10 HEPES, 4 MgATP, 0.4 NaGTP and 10 phosphocreatine di(tris)salt
(adjusted to pH 7.2 with Tris(hydroxymethyl) aminomethane. CCK-4 and the HC-070 were
applied to the superfusion solution via a gravity-driven application system.
Currents were filtered at 2.9 kHz and digitized at 10 kHz. Spontaneous postsynaptic cur-
rents were detected using Mini Analysis 6.0.3 software (Synaptosoft) and the amplitude of cur-
rents was measured as the difference between the mean current during a pre-current baseline
over a 2 ms window and the current at its peak.
Animal Welfare
All experimental procedures were authorized by the Local Animal Care and Use Committee in
accordance with local animal care guidelines, AAALAC regulations and the USDA Animal
Welfare Act. For the EPM, some FST, marble burying, experiments were approved by the
Hydra Biosciences Institutional Animal Care and Use Committee (IACUC), governed by the
rules and regulations of the Cambridge Public Health Department and the Commissioner of
Laboratory Animals (Cambridge, MA, USA). The elevated plus maze with CCK-4, some FST,
TST and locomotor activity experiments were conducted at Boehringer Ingelheim, Biberach,
Germany, in accordance with the German and European Animal Welfare Act and authorized
by the Regierungspra¨sidium Tu¨bingen as the responsible local German authority. The chronic
social defeat work was conducted under a permit (170/2012) issued by the Veterinary Office,
Zurich, Switzerland. All efforts were made to minimize the number of mice used and any
stress to the animals.
Pharmacokinetic studies
For the intravenous (IV) group HC-070 was dissolved in 4% DMSO, 10% Solutol HS-15, and
86% water and administered as a bolus via the tail vein (0.25 mg/mL @ 4 mL/kg = 1 mg/kg) to
male C57BL/6 mice or Swiss Webster mice. Oral doses were given at 1 mg/mL at a 10 mL/kg
dose volume to yield a final dose of 10 mg/kg in the fed state. A simple suspension of HC-070
in 0.5% methyl cellulose was used for oral administration. 12 animals were dosed per arm.
Two blood samples per mouse were taken, either via retroorbital or submandibular bleed at
pre-determined time points following compound administration. The second sampling was
done under terminal anaesthesia. Blood samples were added to EDTA microtainers and placed
on wet ice for no longer than 30 minutes prior to being spun at 8000 rpm for 5 minutes to
yield at least 100 μL of plasma. Plasma samples were immediately drawn off, transferred to 1.7
mL Eppendorf tubes, and placed on dry ice/-80˚C prior to analysis. One plasma sample from
each of 3 mice was collected per sampling time point. In the intravenous arm of the study with
Swiss Webster mice, two of the 24 samples could not be taken and the analytical data for one
sample were invalid resulting in 21 valid data points for this arm of the study.
At study termination, animals were sacrificed via CO2 inhalation and blood was collected.
The collection timepoints were recorded and used in subsequent analysis.
Bioanalytical
Plasma samples along with samples of dose solution were analyzed by protein precipitation
followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The triple
quadrupole mass spectrometer was operated in positive ion mode. Brain was homogenized
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in ice cold water (2 mL/brain) and diluted 1 to 4 in plasma prior to analysis. Brain slices
were homogenized in ice cold water (40μL/10mg brain slice) without further dilution prior
to quantification.
Calculating PK properties
The HC-070 concentration data were determined and the concentration-time relationship was
analyzed by a pharmacokinetic data analysis software package (ToxKin1, Version 3, Boehrin-
ger Ingelheim, Germany) to obtain pharmacokinetic parameters. AUC was calculated using
the linear trapezoidal rule for ascending and the logarithmic trapezoidal rule for descending
parts of the concentration-time curve. For IV dosing, concentration at time zero was estimated
by linear interpolation of the concentrations from the two first sampling points.
Brain homogenate assay
Frozen rat brains were homogenized in PBS buffer (dilution factor D = 4). The homogenate
was spiked with test compounds (1 μM final concentration, final concentration of DMSO was
0.1%) and subsequently dialyzed against PBS buffer for 8 hrs at 37˚C in rapid equilibrium dial-
ysis cells (RED-device, Pierce). At the end of the dialysis period, the dialysate was transferred
into reaction tubes and mixed with an analytical internal standard. Tissue homogenate was
added to buffer samples and buffer was added to tissue samples to ensure identical matrix
composition for bioanalytical measurement. After protein precipitation using acetonitrile,
samples were measured by LC-MS/MS. The free fraction was calculated as fu,app = (CPBS/
Chomogenate). Since the brains were homogenized in the buffer, the observed free fraction values
(fu,app) were extrapolated to the fractions unbound in the brain (fu) based on the dilution
(D) using the following formula:
fu ¼ ð1=DÞ=ðð1=fu; app   1Þ þ 1=DÞ:
Unbound brain concentrations are very comparable over species [36] allowing the calcula-
tion of unbound mouse brain concentrations by using rat brain homogenate data.
Elevated plus maze with CCK-4
The EPM is a cross-shaped platform consisting of four equally sized arms (50 cm × 10 cm) ele-
vated 50 cm above ground. There are 2 closed arms (opposing each other), flanked by 40-cm
opaque walls, while the remaining two arms are without walls (open arms). All arms are con-
nected via a central zone (10 cm × 10 cm), allowing animals to move freely into each zone of
the maze.
Male C57BL/6 mice were obtained from Charles River Labs (Charles River, Germany). Ani-
mals weighing 30±1 g were housed in groups of five and kept at 21–23 ˚C under a 12-h regular
light/dark cycle with lights on at 6:00 a.m.
For this paradigm, light intensities in the central zone were set to 100 lux. Animals were
habituated to experimental conditions, but not to the maze. Their movements on the platform
were monitored for a 5-min period with a camera. The animal was initially placed in the cen-
tral zone facing an open arm. Percentage of time spent in open arms (time in open arms/[time
in open arms + time in closed arms] × 100), as well as the number of entries in opened and
closed arms were analyzed with the ANY-maze software (Stoelting Co.). A zone entry was
defined as the presence of 85% of the animal’s body in a specific zone.
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Standard elevated plus maze
The room was illuminated with fluorescent lighting on a 12-hour light/dark cycle. The light
cycle was reversed, so that the dark cycle was from 6am-6pm daily and studies were performed
when animals were more active. Groups of male C57/BL6 mice (10 weeks old, Jackson Labs,
Bar Harbor, ME, USA) were dosed PO with 0.5% methyl cellulose or HC-070 at 0.3, 1 or 3 mg/
kg (n = 10). The positive control, 1.5 mg/kg diazepam, was administered IP 30 minutes prior
to testing (n = 10). Immediately following dosing, mice were returned to their home cage. At
60 minutes post vehicle or HC-070 administration, and 30 minutes post diazepam administra-
tion, mice were placed onto the elevated plus maze (0547M, Mouse Elevated Plus Maze,
Columbus Instruments, Columbus, OH), one at a time, and their session recorded for 5 min-
utes. Videos were manually scored for number of open arm entries by a scorer blinded to treat-
ment. All animals that fell off the maze during the test were removed from analysis.
Separate groups of satellite animals (n = 3/group) were dosed with 0.3, 1 and 3 mg/kg HC-
070. These animals were sacrificed via CO2 narcosis at 1 hour post dose and plasma and brains
harvested to determine levels of HC-070.
Chronic social defeat
C57BL/6J mice bred in-house (Zurich) were used in these experiments. Male offspring were
weaned aged 3 weeks and caged in groups of 2–3 littermates. Mice were aged 12 weeks and
weighed 26–30 g at study onset. Aggressor mice were male CD-1 (Janvier Labs, Saint-Berthe-
vin, France). They were aged 8 months, were ex-breeders, and caged singly. Mice were main-
tained on a reversed 12:12 h light-dark cycle in an individually-ventilated caging system.
Chronic social defeat (CSD) was conducted using a refined protocol as described elsewhere
[37]. Briefly, a C57BL/6 (CSD) mouse was housed singly in the home cage of a CD-1 mouse
separated by a transparent, perforated divider. The CSD mouse was placed with the CD-1
mouse for either a cumulative total of 60 sec physical attack or 10 min maximum. To avoid
bite wounds, the lower incisors of CD-1 mice were trimmed every third day across CSD. Each
day for 15 days, the CSD x CD-1 mouse pairings were rotated so that CSS mice were con-
fronted daily with a novel CD-1 mouse. On days 16–18, CSD mice remained adjacent to the
same CD-1 mouse without any further attacks. Control (CON) mice remained in littermate
pairs and were handled and weighed daily. Mice were weighed daily, and a reduction below
90% body weight at experiment onset was used as one discontinuation measure; as in previous
CSD studies (e.g. 19, 20), no mouse went below 95% onset body weight on any day during the
experiment and all mice maintained or increased absolute body weight across the experiment.
After each CSD session mice were checked for bite wounds: as noted above, a major refine-
ment of our CSD protocol over similar protocols [38] is that the lower incisors of CD-1 mice
are trimmed regularly to prevent bite wounds. This refinement, and also that of observing and
limiting each CSD session to a maximum of 60 s attack time, results in the complete absence of
deep bite wounds (skin penetration) (19, 20). A localized surface wound (skin abrasion) was
received once by each of four CSD mice and the discontinuation measure of three surface
wounds did not occur in any mouse.
Pavlovian fear learning and memory
Behavioral testing was conducted under dim lighting in a room adjacent to the holding room,
using a Multi-Conditioning System with an infrared movement-detection system (TSE Sys-
tems GmbH, Bad Homburg, Germany) [39]. The test comprised four stages, each conducted
in the same arena (context): pre-exposure to the arena (context), tone-footshock fear condi-
tioning, fear expression to the context and fear expression to the tone. The tone served as
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conditioned stimulus (CS); it was paired with footshock which was the aversive unconditioned
stimulus (US). The conditioning and expression stages of Pavlovian learning are inter-depen-
dent in that what is learned during the conditioning stage determines what can be consolidated
and recalled during the expression stage. Freezing was the readout for fear conditioning and
expression, defined as no detectable movement for at least 2 sec; freezing was measured as per-
cent time spent in this state. Locomotor activity was also measured continuously.
Context pre-exposure. The mouse was placed on the grid floor in the arena (context) for
15 min, and activity and % time freezing were recorded continuously.
CS-US fear conditioning. The next day, the mouse was placed on the grid floor in the
same context and, following 5-min adaptation, exposed to six trials of a discrete, neutral tone
of 5 kHz and 85 dB (CS) presented via a speaker for 20 seconds; the final 2 seconds were con-
tiguous with a 2 second x 0.15 mA footshock (US). The inter-trial interval (ITI) was 120 s. Per-
cent time freezing was measured during the six CSs and five ITIs; for analysis, these trials were
grouped into CS blocks 1–2, 3–4, 5–6.
Context fear expression. The next day, the mouse was placed on the grid floor in the
same arena for 21 min. Percent time freezing was measured and for analysis time was grouped
into 3-min blocks.
CS fear expression. Immediately after the context fear expression test, mice were exposed
to 12 trials of the tone CS for 30 sec and with an ITI of 90 sec. Percent time freezing was mea-
sured during the 12 CSs and 11 ITIs; for analysis, trials were grouped into CS blocks 1–3, 4–6,
7–9, 10–12 and ITIs 1, 2–3, 4–5, 6–7, 8–9, 10–11.
Experimental design. In week 1 of each experiment, mice were handled on five consecu-
tive days. In a first experiment, we investigated for effects of HC-070 on Pavlovian fear learn-
ing and memory in otherwise non-manipulated mice. Mice (n = 10 per group) were allocated
at random to the 0, 1 or 3 mg/kg group, and the same dose was administered at 2 h before the
CS-US conditioning test and, on the next day, at 2 h before the onset of the two expression
tests. In a second experiment, we investigated for effects of HC-070 on Pavlovian fear learning
and memory in CSD versus control (CON) mice. An initial context pre-exposure test was con-
ducted prior to CSD to determine baseline freezing levels; these were used to counterbalance
allocation of mice to CSD and CON groups. Following 15 days of CSD/CON, within each
group mice were allocated at random to vehicle (VEH) or HC-070 1 mg/kg, giving four groups
and 12 mice per group. On day 16 another context pre-exposure test was conducted, on day 17
the CS-US conditioning test, and day 18 the two expression tests. VEH or HC-070 were
administered at 5 min after the CS-US conditioning test and at 1 h prior to the onset of the
two expression tests. At the end of testing mice were decapitated and trunk blood was collected
into EDTA-coated tubes.
Marble burying
Groups of female C57BL/6 mice (7 weeks old, Charles River Laboratories, Wilmington, MA
USA) were dosed PO with 0.5% methyl cellulose or HC-070 at 1, 3 or 10 mg/kg (n = 10). The
positive control, 10 mg/kg zimelidine, was administered intraperitoneally 45 minutes prior to
testing (n = 10). Immediately following dosing, mice were returned to their home cage. At 60
minutes post vehicle or HC-070 administration, and 45 minutes post zimelidine administra-
tion, mice were placed into the larger cages containing 20 black glass marbles evenly spaced
over 5 cm of BetaChip bedding for a 30 minute test session. Upon completion, the animals
were carefully removed and each cage was photographed for later review. The animals were
sacrificed via CO2 narcosis upon removal from the cages and plasma was harvested to deter-
mine levels of HC-070.
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Photos were manually scored for number of unburied marbles (>25% visible) by a scorer
blinded to treatment. The number of buried marbles is equal to the number of unburied mar-
bles subtracted from 20.
Tail suspension test
NMRI mice were habituated to their room for at least 2 to 3 weeks after the delivery and kept
under standard conditions in groups of 4–5 animals per cage. Food and water were available
ad libitum.
The tail suspension test was performed using with a BIOSEB system. In preparation for the
experiment, a piece of tape (approx. 15 cm long) was wrapped around the end of the mouse
tail approximately 2 mm before the tip. The tape was then attached to a holding device within
the measuring unit at a height of approximately 30cm.
Movements of the animals were monitored and automatically evaluated by corresponding
software. The duration of immobility during 6 min observation period was recorded. At the
end of the experiment plasma samples were taken and the animals were sacrificed via isofluor-
ane inhalation and subsequent decapitation.
Locomotor activity
NMRI mice were habituated to their room for at least 2 weeks after the delivery and kept
under standard conditions in groups of 4–5 animals per cage. Food and water were available
ad libitum.
Spontaneous motility and rearing were measured by an automated system (Coulbourn
Instruments, USA). Animals were introduced into transparent square cages (40 cm length)
that are equipped with 2 light barrier systems in order to monitor the movements as well as
rearing behavior automatically. The movements of the animals were recorded for 30 minutes.
At the end of the experiment, the animals were sacrificed via isofluorane inhalation and subse-
quent decapitation.
Forced swim test
For the initial forced swim test work performed in the US, Groups of male CD-1 mice (7
weeks old, Charles River Labs, Wilmington, MA, USA) were dosed PO with 0.5% methyl cellu-
lose or HC-070 at 0.3, 1 or 3 mg/kg (n = 12/dose). The positive control, imipramine, was
administered IP at 20 mg/kg (n = 12). Immediately following dosing, mice were returned to
their home cage. At 60 minutes post vehicle or HC-070 administration, and 45 minutes post
imipramine administration, 4 mice were placed individually into chambers filled with 15 cm
of water, maintained at a temperature of 24±1˚C. After a 6-min swim session mice were towel-
dried and returned to the home cage.
Digital video output of swim sessions was analyzed by a computer running Noldus (Ethovi-
sion XT Version 8 Video Tracking, Noldus Information Technology, Wageningen, Nether-
lands) software. Individual mouse immobility time is acquired and the last 4 minutes of the
6-minute swim session analyzed. The software traces each animal’s displacement in a defined
arena; images of these displacements are acquired five times per second.
For the confirmatory forced swim test work performed in Germany, male C57BL/6 mice
were obtained from Charles River Labs (Charles River, Germany). HC-070 was administered 1
hour prior to testing. Mice were gently placed into a 1 liter glass beaker (height: 14.5 cm, diam-
eter: 11 cm) containing 650 ml (7.5 cm height) water at temperature of 21–22˚C, for 5 min.
During the FST, animals were constantly monitored by video recording and data collected
for the entire 5 min period. The duration of animal immobility within the last 2 min was
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evaluated. A mouse was considered immobile when it ceased struggling and remained floating
in the water making only those movements necessary to keep its head above the water. Ani-
mals were assigned to dose groups at random. Groups were equally divided among five test
beakers. The positive control desipramine was administered IP at 15 mg/kg (8 ml/kg) 60 min
prior to the test. After a 5 min swim session mice were towel-dried under heated red light
and returned to the home cage. Aliquots of each dosing solution were collected on each study
day and stored at -20˚C prior to analysis. Ten to fifteen minutes after FST, blood was collected
into tubes containing EDTA (1.6 mg/ml) and centrifuged at 3000 x g for 20 min at 4˚C. Then,
plasma was stored at -20˚C until compound level determination.
For the PK/PD modeling, results were combined from both sets of forced swim test work.
Statistical analysis
For the analysis of the slice recordings, a two-way ANOVA followed by a Tukey’s multiple
comparison’s test was used to compare the EPSCs evoked by CCK-4 in the presence and
absence of HC-070.
For all acute in vivo tests, a one-way ANOVA was used to determine statistical significance
for effect of HC-070 versus the vehicle followed by a Dunnett’s test for post-hoc significance. A
one or two-tailed t-test was used to determine the statistical significance of the reference com-
pounds versus the vehicle control group.
For the fear conditioning and chronic social defeat work, statistical analysis of % time spent
freezing was conducted using SPSS (version 20, SPSS Inc., Chicago IL, USA) and mixed model
ANOVA. In the first experiment the design was drug dose (0, 1, 3 mg/kg) X Trial-block (ITI or
CS trial blocks), and in the second experiment the design was Group (CON-VEH, CON-Drug,
CSS-VEH, CSS-Drug) X Trial-block (ITI or CS trial blocks). Significant effects were analyzed
using Fisher’s least significant difference (LSD) post hoc test.
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S1 Table. Potency of HC-608 at recombinant TRPC4 and TRPC5 containing channels. :
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S1 Fig. Time course of responses following compound and agonist addition in TRPC5 and
TRPC4 expressing cells. (A & B) Time course of cells expressing TRPC5 in the fluorometric
assays. Cells plated into 384 black wall clear bottom plates were loaded with the fluorescent cal-
cium indicator Fluo-4AM and the fluorescence intensity of each well was determined periodi-
cally over the course of ~5 minutes. The raw fluorescence in each well at each time point was
divided by the initial fluorescence in each well. HC-070 (A) or HC-608 (B) (blue symbols) at
the indicated concentration was added at the indicated time point and cells were incubated for
~2 minutes. High calcium buffer was added at the time point indicated and the responses moni-
tored for ~2.5 minutes. Values at the indicated time points were averaged to determine the
response to agonist. Negative control wells (black symbols) which received only the compound
vehicle and assay buffer were included on each plate as were positive control wells (grey sym-
bols) containing the 2-APB. (C & D) Time course of cells expressing TRPC4 in the fluorometric
assays. Cells plated into 384 black wall clear bottom plates were loaded with the fluorescent cal-
cium indicator Fluo-4AM and the fluorescence intensity of each well was determined periodi-
cally over the course of ~5 minutes. The raw fluorescence in each well at each time point was
divided by the initial fluorescence in each well. HC-070 (C) or HC-608 (D) (blue symbols) at
the indicated concentration was added at the indicated time point and cells were incubated for
~2 minutes. High calcium buffer containing Carbachol (7 μM final concentration) was added at
the time point indicated and the responses monitored for ~2.5 minutes. Values at the indicated
time points were averaged to determine the response to agonist. Negative control wells (black
symbols) which received only the compound vehicle and assay buffer were included on each
plate as were positive control wells (grey symbols) containing the 2-APB.
(TIF)
S2 Fig. Pharmacokinetic properties of HC-070. PK profiles of HC-070 after (A) intravenous
and (B) oral administration in Swiss Webster mice. Plasma concentrations were determined
by LC-MS/MS. Points represent the individual concentrations at the times indicated. Lines
represent mean exposure (n = 12 mice/arm). (C) Summary of PK properties. CL = clearance;
Vss = volume of distribution at steady state; MRTdisp = mean residence time of drug molecules
after intravascular administration; T1/2 = half-life. (D) Plasma and brain concentrations mea-
sured 2 hours after intravenous or oral administration of 1 or 10 mg/kg HC-070, respectively.
CPL = concentration in plasma, CBR = concentration in brain, KP,BR = partitioning coefficient
between brain and plasma.
(TIF)
S3 Fig. Control experiment for the chronic social defeat-fear conditioning study. (A) With-
out drug administration, when placed in an unfamiliar arena (context), mice showed a low
level of freezing, a fear behavior. (B) The next day, mice were administered vehicle, 1 or 3 mg/
kg HC-070 PO and 2 hours later were placed in the same context, and exposed to a tone condi-
tioned stimulus (CS) that announced an electroshock unconditioned stimulus (US). Mice
acquired increased CS freezing across successive pairings of the CS and US, indicating the
learning of fear of the CS, without an effect of HC-070. (C) The next day, mice received vehicle,
1 or 3 mg/kg HC-070 PO (same dose allocation as on previous day) and 2 hours later were
placed in the same context in which CS-US conditioning took place the previous day. HC-070
was without effect on context fear memory, as indicated by each drug group showing low and
similar freezing levels. (D) Immediately after the context memory test, mice were presented
with the tone CS memory test. Freezing to the CS was higher than to the context, but there was
still no effect of HC-070 on CS fear memory in these otherwise non-manipulated mice.
(TIF)
HC-070, a TRPC4/5 inhibitor, ameliorates behaviors associated with anxiety and depression in mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0191225 January 31, 2018 28 / 32
S4 Fig. Effects of positive control PCP on locomotor activity. After 90 minutes of habitua-
tion to the chamber, mice were administered vehicle or 5 mg/kg PCP subcutaneously. Activity
was recorded for another 60 minutes. PCP substantially increased activity, as expected. (2-way
ANOVA followed by a Dunnett’s multiple comparison’s test, p<0.0001; n = 8/group).
(TIF)
S1 Report. In vitro Pharmacology Study of HC-070.
(PDF)
S2 Report. In vitro Pharmacology Study of HC-608.
(PDF)
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